European Pharmaceutical Review

OCTOBER 7, 2022

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

Express Pharma

MARCH 20, 2025

GlobalDatas report, Endometriosis Market Size and Trend Report, reveals that the endometriosis market size across the seven major markets* (7MM) is expected to achieve a compound annual growth rate of more than 9 per cent during 2020-2030.

Dosage 66

Dosage Compounding Hospitals 66

Express Pharma

JANUARY 2, 2025

million by 2030. Lyophilization is a crucial process in preserving the stability and shelf life of pharmaceutical products, especially for sensitive chemical compounds. The post Akums announces new facility for lyophilized and sterile dosage manufacturing appeared first on Express Pharma. With a CAGR of 5.6

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. This represents a compound annual growth rate (CAGR) of close to 10 percent. According to the report buccal delivery is the “most feasible and preferred choice compared to oral dosage forms, particularly among elderly patients.” billion in 2023 to $7.13

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

FEBRUARY 3, 2023

The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance.

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98